CL King initiated coverage of Haemonetics with a Buy rating and $116 price target. Haemonetics’ transformational growth journey should continue to create value for shareholders, the analyst tells investors in a research note. The firm likes the diversification story into hospital products and thinks it will help fuel growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: